All Stories

Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine and laying off an undisclosed number of staffers.

May 19, 2025 - 21:30
 0
Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff
Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine and laying off an undisclosed number of staffers.
Read More

Tags:

Previous Article

ViiV Healthcare retakes first place in pharma reputation ranking among US patien...

Next Article

Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Prime trims team...

Related Posts

Innovative Breakthrough in Cancer Testing Developed in Ohio

Innovative Breakthrough in Cancer Testing Developed in ...

May 19, 2025  0

ASGCT: Neurogene details new safety measures after young patient's death in AAV gene therapy trial

ASGCT: Neurogene details new safety measures after youn...

May 16, 2025  0

GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug

GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead...

May 14, 2025  0